์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ
Merck

Y0000698

Paclitaxel

European Pharmacopoeia (EP) Reference Standard

์กฐ์ง ๋ฐ ๊ณ„์•ฝ ๊ฐ€๊ฒฉ์„ ๋ณด๋ ค๋ฉด ๋ฅผ ํด๋ฆญํ•ฉ๋‹ˆ๋‹ค.

ํฌ๊ธฐ ์„ ํƒ

๋ณด๊ธฐ ๋ณ€๊ฒฝ

์ œํ’ˆ์ •๋ณด (DICE ๋ฐฐ์†ก ์‹œ ๋น„์šฉ ๋ณ„๋„)

์‹คํ—˜์‹(Hill ํ‘œ๊ธฐ๋ฒ•):
C47H51NO14
CAS ๋ฒˆํ˜ธ:
Molecular Weight:
853.91
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
1420457
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜


grade

pharmaceutical primary standard

API family

paclitaxel

manufacturer/tradename

EDQM

mp

213 ยฐC (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8ยฐC

SMILES string

[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7

InChI

1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1

InChI key

RCINICONZNJXQF-MZXODVADSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Paclitaxel EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Paclitaxel is a potent anti-neoplastic and anti-mitotic taxane drug, which binds to the N-terminus of ฮฒ-tubulin and and stabilizes microtubules arresting the cell cycle at the G2/M phase.
Paclitaxel is a potent anti-neoplastic and anti-mitotic taxane drug, which binds to the N-terminus of ฮฒ-tubulin and and stabilizes microtubules arresting the cell cycle at the G2/M phase. The microtubule damage induces apoptosis through a JNK-dependent pathway followed by a JNK-independent pathway, perhaps related to the activation of protein kinase A (PKA) or of Raf-1 kinase, resulting in phosphorylation of Bcl-2. A major metabolite via CYP2CB is 6ฮฑ-hydroxypaclitaxel (6ฮฑ-OHP).

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Disclaimer

Paclitaxel undergoes transesterification in methanol and hydrolyzes in aqueous solutions.


Still not finding the right product?

Explore all of our products under Paclitaxel


pictograms

Health hazard

signalword

Danger

Hazard Classifications

Muta. 2 - Repr. 1B - STOT RE 1

target_organs

Central nervous system,Bone marrow,Cardio-vascular system

์ €์žฅ ๋“ฑ๊ธ‰

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



๊ฐ€์žฅ ์ตœ์‹  ๋ฒ„์ „ ์ค‘ ํ•˜๋‚˜๋ฅผ ์„ ํƒํ•˜์„ธ์š”:

์‹œํ—˜ ์„ฑ์ ์„œ(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our ๋ฌธ์„œ section.

๋„์›€์ด ํ•„์š”ํ•˜์‹œ๋ฉด ์—ฐ๋ฝํ•˜์„ธ์š”. ๊ณ ๊ฐ ์ง€์› ๋ถ€์„œ

์ด ์ œํ’ˆ์„ ์ด๋ฏธ ๊ฐ€์ง€๊ณ  ๊ณ„์‹ญ๋‹ˆ๊นŒ?

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ์—์„œ ์ตœ๊ทผ์— ๊ตฌ๋งคํ•œ ์ œํ’ˆ์— ๋Œ€ํ•œ ๋ฌธ์„œ๋ฅผ ์ฐพ์•„๋ณด์„ธ์š”.

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ ๋ฐฉ๋ฌธ